Form 4: United Therapeutics Director Dwek Exercises Share Tracking Awards and Disposes of Common Stock

Director Raymond Dwek executed share tracking awards and disposed of common stock of United Therapeutics Corp on April 8, 2024, according to a Form 4 filing.

Summary

• Raymond Dwek, a director of United Therapeutics Corp, executed share tracking awards and disposed of common stock on April 8, 2024.
• The transactions were made pursuant to a Rule 10b5-1 trading plan entered into on November 27, 2023.
• Dwek exercised 4,000 share tracking awards at a price of $88.03, receiving cash.
• Dwek also disposed of 4,000 shares of common stock at $236.96 per share.
• Following these transactions, Dwek directly owns 1,750 shares of common stock and 6,000 share tracking awards.

Sentiment

Score: 5

Explanation: The filing represents routine insider transactions under a pre-arranged trading plan, indicating a neutral sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings to gain insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly listed companies like United Therapeutics (UTHR).
• Comparable companies such as Gilead Sciences (GILD) and Amgen (AMGN) also regularly report Form 4 filings related to their executives' stock transactions.
• The use of Rule 10b5-1 trading plans is a standard practice among corporate insiders to avoid accusations of trading on non-public information.
• The size and frequency of these transactions are typical for directors and officers in similar roles at other biotech firms.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a director.
• The impact is likely minimal as the transactions were conducted under a pre-arranged trading plan.

Key Dates